News & Trends - Biotechnology
Regenerative medicine industry poised for continued growth
Regenerative medicine, cell and gene therapy, is poised for continued expansion in 2020, after the latest global industry briefing reveals another year of significant growth, and total global financings the second highest yet.
Released at Biotech Showcase last week, the Alliance for Regenerative Medicine (ARM)’s State of the Industry presentation showed the US$9.8B of total global financing in 2019 was attributed to gene-based therapies, cell therapies, and tissue engineering.
Financing remains strong across venture capital and partnerships, with M&A activity showcasing large and middle cap pharma’s interest in the cell and gene therapy space.
The pipeline is robust, with several next-generation technologies entering the clinic, and an increase in clinical trials for indications with large patient populations. As at the end of 2019, there were a recorded 1,066 clinical trials underway, with 58% of phase I trials in gene-modified cell therapies.
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
Considerable effort and progress in addressing various manufacturing challenges are being made, with in-house manufacturing capabilities becoming a strategic priority, companies investing in manufacturing earlier in the development process, and CMOs becoming attractive acquisition targets.
AusBiotech is a member of ARM, an international community of over 350 small and large companies, non-profit research institutions, patient organisations, and other sector stakeholders dedicated to realising the promise of regenerative medicine for patients around the world.
Enhance employer branding and boost thought leadership in the industry to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting your organisation to Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our unique media solutions.
News & Trends - Pharmaceuticals
Roche’s immunotherapy drug shows promising results for Australian patients with rare blood cancer
Pharma News: Roche’s immunotherapy drug has shown high response rates in patients with a rare form of blood cancer that […]
MoreNews & Trends - Pharmaceuticals
Government seals deal with industry for rare cancer therapy
Pharma News: Australian children and young adults diagnosed with high-risk neuroblastoma will continue to receive free access to a promising, […]
MoreNews & Trends - MedTech & Diagnostics
Abbott showcases leadless pacemaker system to local stakeholders
MedTech & Diagnostics News: Leadless pacemakers are promising alternatives to transvenous pacing. Abbott hosted a stakeholder event at the recent […]
MoreNews & Trends - Pharmaceuticals
Australian scientists pivotal in new drug class from BMS
Pharma News: The first new class of drug for schizophrenia in decades has been approved, offering a fresh approach by […]
More